抗血管生成靶向药物药源性高血压的机制及其临床意义

整理：肿瘤资讯

来源：天晴肿瘤时讯

参考文献

[1] Adverseeffects of anticancer agents that target the VEGF pathway,Nat Rev Clin Oncol. 2009 Aug;6(8):465-77

[2] 高血压与安罗替尼治疗二线及以上晚期食管鳞癌的疗效相关性分析 2019 CSCO

[3] Evaluation ofhypertension and hand-foot syndrome as markers of anlotinib efficacy inadvanced soft tissue sarcoma2018 ESMO，abs 1633

[4] Retrospective analysis ofbevacizumab-induced hypertension and clinical outcome in patients withcolorectal cancer and lung cancer，Cancer Medicine 2016; 5(7):1381

[5] Correlation of bevacizumab-induced hypertension andoutcomes of metastatic colorectal cancer patients treated with bevacizumab: asystematic review and meta-analysis，World J Surg Oncol.2013 Nov 28;11:306

[6] Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer:an updated meta-analysis,Aging (Albany NY). 2018 Jun21;10(6):1424

[7] Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in  second-line treatment of gastric cancer,Gastric Cancer. 2018 Mar;21(2):276 

[8] Tolerability of nintedanib (BIBF 1120) incombination with docetaxel: a phase 1 study in Japanese patients with previouslytreated non-small-cell lung cancer,J Thorac Oncol 2015，10(2):346-52